VBU Metrics Metrics Metrics!

Quote

anonymous

Guest
Does leadership really believe that seeing 8 HCPs a day & 60% OEs will grow Shingrix?? They definitely have their heads in the sand! They don’t seem to care about the quality of our calls, only the quantity! This is the worst sales model I’ve ever seen for the VBU. This used to be one of the best divisions; sadly not anymore. Their metric expectations are unrealistic & will not drive business. They need to wake up & realize this isn’t working!
 


Usually when it comes to these types of expectations, upper leadership is desperately trying to save their own jobs. Sad what has become of the VBU…how soon they forget we launched two of the most successful vaccines in last decade for GSK and pharma industry. Shx & Arx!.
 


If you are not measuring, then you are not managing… It’s the lazy unproductive reps that should be concerned. If everyone keeps it real, then the expectations will be adjusted accordingly.
 


anonymous said:
If you are not measuring, then you are not managing… It’s the lazy unproductive reps that should be concerned. If everyone keeps it real, then the expectations will be adjusted accordingly.
Click to expand...
If metrics are the only way you can tell how effective reps are, then you’re a terrible manager. Metrics can be fake or at the very least misleading.
 


Poster #4 you are absolutely right! These metrics are not going to pull Shingrix out of the hole. Shingrix has been tanking consistently for the past 2 or 3 years! These metrics do not measure how effective a rep. is at selling! The fact that the nation cannot even reach the 60% for OE tells you that this is a very unrealistic metric! The VBU has the worse upper leadership! Joaquin has no clue about selling vaccines, and is driving this division further into the ground! Very sad to see and experience the rapid decline of the VBU from what it was when we had Al as our leader.
 




anonymous said:
Usually when it comes to these types of expectations, upper leadership is desperately trying to save their own jobs. Sad what has become of the VBU…how soon they forget we launched two of the most successful vaccines in last decade for GSK and pharma industry. Shx & Arx!.
Click to expand...
Launched two of the most successful vaccines in the last decade? Arexvy!? That’s actually hilarious. Arexvy had one good season, the first season. GSK won the battle and lost the war. Then ACIP decided how unnecessary it was and only recommended it for 75+ or 60+ with comorbidities. The RSV vaccine landscape was decimated by those reco’s. The 50+ indication will never get a recommendation from ACIP. It’s a bad cold for most adults. Vaccine fatigue and hesitancy will turn Arexvy into a huge dud. Shingrix launch was far from successful. You must have forgotten about going around apologizing to doctors that their office could only get 10 doses every 60 days. It was a good vaccine and a terrible launch. Waiting lists at pharmacies, not being able to produce enough doses, yeah, super duper launch. And I said Shingrix WAS a good vaccine (as in past tense) because nobody is getting it anymore. Thus the tanking of Shingrix numbers thus the micromanagement thus the unrealistic goals for the next 6 weeks that nobody will hit. 15% growth in 6 weeks. lol. Good luck.
 




anonymous said:
If metrics are the only way you can tell how effective reps are, then you’re a terrible manager. Metrics can be fake or at the very least misleading.
Click to expand...
Unfortunately there are a lot of horrible managers in the VBU. If they think metrics are going to achieve a 15% increase in shingrix in 6 weeks, I have some swampland to sell them. They know these numbers aren’t attainable but they’re all yes men and women who will do anything and everything to save their own ass. Reps can put whatever the hell they want into Veeva to fake calls. Trust me it’s done regularly. Why do you think they wanted to track everyone’s cars. Here’s the thing. You could see 12 doctors a day and you’re not moving the Shingrix needle. You’ll never get to that 15% growth in 6 weeks or 6 months or 6 years. Vaccine Fatigue is real and 8 years post launch, it’s never getting to the unrealistic expectations from the company. Good luck with that 15% growth.
 


anonymous said:
Launched two of the most successful vaccines in the last decade? Arexvy!? That’s actually hilarious. Arexvy had one good season, the first season. GSK won the battle and lost the war. Then ACIP decided how unnecessary it was and only recommended it for 75+ or 60+ with comorbidities. The RSV vaccine landscape was decimated by those reco’s. The 50+ indication will never get a recommendation from ACIP. It’s a bad cold for most adults. Vaccine fatigue and hesitancy will turn Arexvy into a huge dud. Shingrix launch was far from successful. You must have forgotten about going around apologizing to doctors that their office could only get 10 doses every 60 days. It was a good vaccine and a terrible launch. Waiting lists at pharmacies, not being able to produce enough doses, yeah, super duper launch. And I said Shingrix WAS a good vaccine (as in past tense) because nobody is getting it anymore. Thus the tanking of Shingrix numbers thus the micromanagement thus the unrealistic goals for the next 6 weeks that nobody will hit. 15% growth in 6 weeks. lol. Good luck.
Click to expand...
Arx since launch is the number one RSV vaccine per doses! And yes one of most successful launches in pharmaceutical industry in last 10 years! Sorry you don’t get that. Shx is a blockbuster success with launches all over world! Yes 15% growth is crazy during next 6 weeks, but it’s all relative to a measured point of time last year. 40% national immunization post launch. Definitely room to go up, but wont be easy, especially with our current leadership driving metrics because they don’t know how else to impact the market. By the way, “shingles doesn’t care” about vaccine fatigue lol!! 1-3 will learn the painful way.
 


anonymous said:
Arx since launch is the number one RSV vaccine per doses! And yes one of most successful launches in pharmaceutical industry in last 10 years! Sorry you don’t get that. Shx is a blockbuster success with launches all over world! Yes 15% growth is crazy during next 6 weeks, but it’s all relative to a measured point of time last year. 40% national immunization post launch. Definitely room to go up, but wont be easy, especially with our current leadership driving metrics because they don’t know how else to impact the market. By the way, “shingles doesn’t care” about vaccine fatigue lol!! 1-3 will learn the painful way.
Click to expand...
Arexvy had one good year. Then Pfizer’s contracting team outperformed GSK’s. No maternal indication for Arexvy either. The RSV market projections by 2030 were cut by 2/3 because ACIP gave very poor recommendations (rightfully). 75+ one dose and 60+ only with comorbidities. Kiss the 50 and over indication bye bye. Arexvy won the battle and lost the war. Shingrix being a blockbuster success, hmm, maybe in the beginning but the numbers from the last 3-4 years speak for themselves. Can you say tanking. And if you don’t say it, leadership will. That’s why the micromanagement is through the roof. Layoffs (via PIP’s) are coming. They know the 15% growth isn’t happening. 40% immunization post launch, congrats but it’s not going up much from there. Most people who wanted shingrix have got it. The IRA already got those who couldn’t afford it so now what’s left is people who don’t want any vaccines (growing by the day) and those on the fence who doctors aren’t spending time trying to convince. Oh, and those turning 50 but most won’t get it at 50. Leadership not knowing how to impact the market and leading through fear and micromanagement is a poor recipe for success. Your last comment reciting the commercials and the incidence of shingrix is embarrassing lol. People don’t care that shingles doesn’t care. The numbers confirm that. Best of luck, there’s no worse division to be in right now than the VBU.
 





Write your reply...
Top Bottom
Back
Quote